Clinical Trials on Prognostic Stage II Breast Cancer AJCC v8 in New Zealand

Total 581 results

Memorial Sloan Kettering Cancer Center

Completed

Glucose Monitoring to Predict and Treat High Glucose Levels After Steroid Treatment

Diabetes | Breast Cancer | Pancreatic Cancer | Pre Diabetes

United States
Gilead Sciences

Completed

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Cervical Cancer | Urinary Bladder Neoplasms | Small Cell Lung Cancer | Hepatocellular Carcinoma | Pancreatic Cancer | Esophageal Cancer | Ovarian Epithelial Cancer | Glioblastoma Multiforme | Gastric Adenocarcinoma | Triple Negative Breast Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Renal Cell Cancer and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Lung Adenocarcinoma | Lung Large Cell Carcinoma | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Minimally Invasive Lung Adenocarcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Lung Squamous Cell Carcinoma | Lung Adenosquamous Carcinoma

United States
National Cancer Institute (NCI)

Completed

Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7

United States
National Cancer Institute (NCI)

Active, not recruiting

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7

United States
Rutgers, The State University of New Jersey

Recruiting

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

Cardiac Toxicity | Early-stage Breast Cancer

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLC

Terminated

Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection

HIV Infection | Unspecified Adult Solid Tumor, Protocol Specific | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Recurrent Breast Cancer | Recurrent Ovarian Epithelial Cancer | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7 | EGFR Exon 19 Deletion Mutation | EGFR NP_005219.2:p.L858R

United States
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Unresectable Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma | Metastatic Papillary Renal Cell Carcinoma | Locally Advanced Papillary Renal Cell Carcinoma

United States, Canada
Sarah Goldberg
Mirati Therapeutics Inc.

Terminated

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

Lung Diseases | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Metastatic Lung Non-Small Cell Carcinoma | PD-L1 Gene Mutation | Pembrolizumab | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Advanced Treatment-Naïve PD-L1 | Sitravatinib

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma

United States, Canada
Sidney Kimmel Cancer Center at Thomas Jefferson...
Novartis; Prostate Cancer Clinical Trials Consortium

Completed

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7 | Prostate Carcinoma Metastatic in the Bone

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Recurrent Endometrial Endometrioid Adenocarcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | Metastatic Endometrial Endometrioid Adenocarcinoma

United States
Sapience Therapeutics

Recruiting

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Breast Cancer | Glioblastoma | Prostate Cancer | Brain Cancer | Glioblastoma Multiforme | GBM | Metastatic Breast Cancer | Recurrent Glioblastoma | Metastatic Melanoma | Metastatic Prostate Cancer | Prostate Cancer Metastatic | Newly Diagnosed Glioblastoma | Melanoma Stage IV | Melanoma Recurrent

United States, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Recurrent Lung Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
National Cancer Institute (NCI)

Completed

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

Neuroendocrine Carcinoma | Small Cell Carcinoma | Extensive Stage Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Large Cell Lung Carcinoma

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Brenner Tumor | Stage II Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian... and other conditions

United States, Japan
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies

Recurrent Adult Acute Myeloid Leukemia | Recurrent Adult Burkitt Lymphoma | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Kidney Medullary Carcinoma | Advanced Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Brenner Tumor | Stage II Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Endometrial Adenocarcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma | Gastrointestinal Complication and other conditions

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Pain | Urinary Complications | Breast Adenocarcinoma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | Metastatic Malignant Neoplasm to the Bone | Musculoskeletal Complication

United States, Puerto Rico
National Cancer Institute (NCI)
Radiation Therapy Oncology Group

Terminated

Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Metastatic Malignant Neoplasm in the Brain | Stage IV Non-Small Cell Lung Cancer AJCC v7

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

KRAS Gene Mutation | Recurrent Lung Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
National Cancer Institute (NCI)

Completed

Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v7

United States, Peru
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells

Atypical Endometrial Hyperplasia | Human Papillomavirus Infection | Stage 0 Cervical Cancer AJCC v7

United States, Korea, Republic of, Japan
National Cancer Institute (NCI)

Active, not recruiting

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v7

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IVB Cervical Cancer AJCC v6 and v7

United States
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Recurrent Esophageal Carcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Stage IV Esophageal Cancer AJCC v7 | Metastatic Esophageal Squamous Cell Carcinoma | Metastatic Esophageal Adenocarcinoma | Recurrent Gastroesophageal Junction Adenocarcinoma | Recurrent Esophageal Adenocarcinoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors

Recurrent Salivary Gland Carcinoma | Salivary Gland Adenoid Cystic Carcinoma | Stage IV Major Salivary Gland Cancer AJCC v7 | Malignant Salivary Gland Neoplasm

United States, Canada
National Cancer Institute (NCI)

Completed

Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States

Clinical Trials on Prognostic Stage II Breast Cancer AJCC v8 in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations